Objective: To analyze the change in health-related quality-of-life (HRQoL) in patients with Parkinson's disease (PD) and to identify different classes of HRQoL decline. Methods: A longitudinal cohort study was performed to assess clinical parameters (unified PD rating scale, Beck Depression Inventory) and HRQoL data (EuroQol, Parkinson's Disease Questionnaire [PDQ]-39) at baseline, 3, 6, 12, 24, and 36 months. A total of 145 patients with PD were consecutively recruited in the county of Northern Hessia, Germany, between January and June 2000. A latent growth mixture model was applied to analyse the heterogeneity in HRQoL trajectories. Results: We successfully applied latent mixture growth modeling in order to identify different classes of HRQoL trajectories in PD. Three growth models were developed and each resulted in a four-class model of distinct patterns using the generic EuroQol instruments' outcomes (EuroQol-5 Dimensions and visual analogue scale) and the disease-specific PDQ-39. The four classes were defined by individual trajectory characteristics. Classes one and two represented trajectories with moderate declines over 36 months, but with different initial intercepts. Class three consisted mainly of patients who passed away during the observation period and therefore had a large HRQoL decline. Class four was characterized by a low level of HRQoL at baseline and a significant subsequent decline. Conclusions: The findings provide a more elaborate understanding of the variability in HRQoL reduction in PD over time. The classification of different HRQoL subgroups may help to explain the response of PD patients to the natural history of the disease. Future research will enable the identification of HRQoL responder subgroups on different treatment regimens.
Introduction
Health-related quality-of-life (HRQoL) has become a key concept in patient-relevant outcomes research. In the absence of biomarkers adequately describing the progression of Parkinson's disease (PD), patient-relevant outcomes are required to ensure that treatments in fact provide substantial benefits and do not only represent physiological surrogates without any influence on the patients' well-being. Disease-specific and generic HRQoL instruments have been developed and used to measure the subjective perception of disease, as well as the improvement or deterioration caused by therapeutic interventions [1] [2] [3] [4] . In cancer for instance, HRQoL measures are already tested for their prognostic value (e.g. [5, 6] ).
For PD, several disease-specific instruments are available and have already been applied in randomized controlled trials as a response measure to therapy -the Parkinson's disease quality-of-life questionnaire (PDQL) [7] and the 39-item Parkinson's disease Questionnaire (PDQ-39) [8 -11] .
The impairment of HRQoL by PD is well described in the literature. The progressive and chronic nature of PD suggests that HRQoL will decline during the course of the disease [2] . Several studies have reported an independent association of decreased HRQoL and more severe (Hoehn and Yahr) disease stages [12] . Furthermore, motor complications such as motor fluctuations, dyskinesias, dystonia, and freezing as well as non-motor complications such as dementia, depression, or psychosis considerably decrease HRQoL [13] . Because HRQoL is a concept that is based on the subjective impression of the patient, it seems probable that determinants of self-perception and differences in coping strategies of the patients, in combination with their clinical and socio-demographic characteristics, influence and determine the change in self-reported HRQoL [14] . Given the large number of influences on HRQoL that may vary between individuals and within individuals over time, much heterogeneity of HRQoL trajectories in patients with PD can be expected.
When revisiting data from one of our own studies, we found that the individual trajectories for EQ-5D and PDQ-39 indeed showed remarkable heterogeneity for the 145 patients followedup for 36 months. The subjects had an almost constant or decreasing quality of life during follow-up ( Fig. 1 [13] ).
In contrast with conventional methods that are used to analyze longitudinal repeated measures, such as analysis of variance, the latent mixture growth model provides a tool for modeling heterogeneity in the individual trajectories across time. The traditional analysis of variance approach is limited by its assumptions regarding missing data and the variancecovariance structure over time. In the analysis of variance with repeated measures, it is assumed that the variance and covariance of the outcome variable are equal over time. This assumption failed for our previous data [13] and the traditional analysis of variance model did not fit the data. The application of growth models (mixed effect models) does not have this stringent assumption about the covariance matrix over time, and provides a flexible approach for longitudinal data modeling. The inclusion of latent variables into the growth model allows for the modeling of heterogeneity in individual trajectories over time. The estimated latent classes are characterized by the homogeneous characteristics of subjects within classes and distinctive characteristics between classes. The latent mixture growth model can be interpreted as a combination of mixed-effects modeling and cluster analysis [15, 16] .
In the current study, we used such models to examine longitudinal changes in HRQoL using generic as well as diseasespecific instruments. Our approach allows for the prediction of distinct classes of HRQoL trajectories based on changes over time and the estimation of the most likely class membership of each individual.
Patients and Methods

Study design
A total of 145 patients (97 male; 48 female) with idiopathic PD were consecutively recruited in the county of North Hessia, Germany, between January and June 2000. A detailed description of the study was reported recently [13] . Briefly, study sites included the Outpatient Department for Movement Disorders, Department of Neurology, PhilippsUniversity Marburg (n=29), the Paracelsus Elena Clinic, Kassel (n=31), two office-based neurologists (n=40), and general practitioners (n=45). Each patient received a structured assessment of parkinsonian signs and neurological symptoms (such as freezing and gait disturbances) conducted by a movement disorders specialist and their medical history was documented. Idiopathic Parkinson's disease was diagnosed according to the clinical criteria of the U.K. Parkinson's disease Society Brain Bank [17] . Patients were examined at baseline (T0), at 3 months (T1), 6 months (T2), 12 months (T3), 24 months (T4), and 36 months (T5). The study was approved by the local ethics committee and all participants gave informed consent.
Evaluation of HRQoL
Patient-reported HRQoL was measured by the generic EuroQol instrument [18] and the Parkinson-specific questionnaire PDQ-39 [19, 20] . The EuroQol is widely used in clinical and economic evaluations. It covers the domains of mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression. A single utility index score (EQ-5D index) is calculated by applying a scoring algorithm [21] . The second part of the EuroQol is a visual analogue scale (EQ-VAS) that is used to mark the patient's current health status on a scale ranging from 0 to 100. The PDQ-39 is a widely used, reliable, and valid PD-specific quality of life instrument. Thirty-nine items examine eight dimensions ("mobility," "activities of daily living," "emotional well-being," "stigma," "social support," "cognition," "communication," and "bodily discomfort") and provide a composite score. Higher values of the PDQ-39 sum score indicate a lower quality of life.
Disease severity
The disease severity in each patient was examined using the Hoehn and Yahr Scale [22] and the unified Parkinson's disease Rating Scale (UPDRS) parts II-IV [23] . UPDRS II assesses activities of daily living (e.g. speech, falling, freezing), UPDRS III comprises a motor examination, including tremor, gait or rigidity, and UPDRS IV describes complications of therapy by means of a) dyskinesias; b) clinical fluctuations; and c) other complications.
Depressive symptoms were assessed by the Beck Depression Inventory (BDI) [24] . This is a reliable and valid measure for use in patients with PD [25] . Higher scores indicate increased depressive symptoms. Cognitive impairment was measured using the Mini Mental State Examination (MMSE). A summary-score of less than 19 was rated as probable cognitive impairment [26] .
Statistical analysis
The analysis was based on 145 patients who participated at baseline (BL). At the 36-month assessment, 23 patients were lost to follow-up because of death, individual reasons (n=22), a too-complex study protocol (n=8), admission into a nursing home (n=1) and other reasons (n=3), resulting in a sample of 88 patients.
The missing values were estimated by full-information maximum-likelihood estimation assuming missing at random, which is a widely accepted method for handling missing data [27, 28] . Twenty-three patients passed away during the 36-month follow-up, and the missing outcome values for these patients were imputed as zero (EuroQoL) or worst possible (PDQ-39), which is, according to the instruments used, the value for the health state 'death' [18, 19] . In addition, the last observations carried forward (LOCF) method and multiple imputation by chained equations (MICE) [29] were used to assess the sensitivity of the latent growth mixture model with respect to missing data modeling. The predictor variables HRQoL at previous assessment (e.g., BL is the previous assessment to 6-month follow-up), UPDRS III, UPDRS IV, BDI, and gender were applied in the MICE approach.
We analyzed each HRQoL measure (EQ-5D, EQ-VAS, and PDQ-39) with a separate latent growth mixture model [16] to identify distinct groups with a common pattern of HRQoL trajectories. The growth factor (slope) was modeled using a piecewise linear function to capture different growth rates for the time intervals BL to 6 months, 6 months to 24 months, and 24 months to 36 months. The intercept parameter (estimated baseline value of the outcome) and the probability of class membership were adjusted for gender and baseline values of UPDRS III, UPDRS IV, and BDI scores in the final models (Fig. 2) . A detailed mathematical presentation of latent growth mixture modeling is provided elsewhere [16, 30] .
In the first step, a single-class model (classical analysis) was specified to investigate the overall growth function for quality of life over time. A mixture growth model with K latent classes (K=2,3, . . .) was formulated to study possible subgroups of patients characterized by class-specific intercepts and slopes in the second step. The number of classes K was chosen by considering the bootstrap likelihood ratio test (BLRT) [31] , which provides a consistently performing model test.
The standard errors of the model parameters (intercept and slope estimates) were estimated by applying a sandwich estimator [32] that took into account the clustered sampling design (patients were clustered within study centers). The parameters were estimated by maximum likelihood. Multiple sets of starting values were applied to avoid local solutions in the estimation procedure. The growth mixture models were estimated for the EQ-5D, EQ-VAS, and PDQ-39 in MPLUS 5.21 [33] . Characterization of the estimated latent classes and subsequent analysis were conducted using STATA 10.2 (Stata Corp., College Station, Texas, USA) [34] .
In more detail, patient's clinical characteristics at baseline were compared across the estimated latent classes by linear regression models for dimensional variables (age, age at symptom onset, duration of disease, Hoehn & Yahr, UPDRS, BDI, MMSE) and logistic regression models for categorical variables (gender, gait disturbances, dyskinesias, falls, fluctuations).
Results
The mean age of the sample of 145 patients was 67.3 years old (95% CI: 65.7-68.8) with 48 females (33.1%). The mean age of PD onset was 57.6 years old (95% CI: 55.6-59.6) and the mean duration of disease was 9.3 years (95% CI: 8.0 -10.5). According to the Hoehn and Yahr scale, 42.8% were stage I/II, 30.3% were stage III, and 26.9% were stage IV/V at baseline. The summary UPDRS (II-IV) score was 48.1 (95% CI: 42.6-53.5). The clinical characteristics of the study sample are reported in Table 1 .
Fifty-seven subjects were lost to follow-up by death (N=23) and other reasons for drop-out (N=34). Baseline characteristics by drop-out status are reported in Table 1 , which can be viewed at: doi:10.1016/j.jval.2010.10.005. Subjects lost to follow-up by other reasons are comparable to subjects followed by the 36-month study period in baseline characteristics. Subjects who died during the study period are characterized by longer duration of Parkinson's disease, higher UPDRS scores, and increased stages in the Hoehn and Yahr scale. The fit for the two-class, three-class, four-class, and fiveclass models with UPDRS III, UPDRS IV, BDI, and gender-adjusted probabilities of class membership and intercept parameters is shown in Table 2 . The four-class model was regarded as the most appropriate to describe the heterogeneity based on a) the comparison of fit indices (Table 2) ; b) the visual comparison of individual trajectories with the estimated unadjusted mean growth curve within class (Fig. 3) ; and c) the number of patients within a class (Table 3) . For example, the fiveclass model does not add information compared to the four-class model for the EQ-5D index (Table 2 ). It simply divides class 4 into two subclasses.
The parameter estimates of the growth curves for the four latent classes of the EQ-5D index, EQ-VAS and PDQ-39 sum score are reported in Table 3 with the baseline value and probability of class membership adjusted for UPDRS III, UPDRS IV, and BDI. The first latent class included patients with a high EQ-5D index at baseline (β=0.99; 95% CI: 0.97-1.00) and a non-significant decrease over time. There was a related pattern for the trajectories in class 2 except that the EQ-5D index at baseline was lower compared to class 1 (β=0.79; 95% CI: 0.75-0.82). In contrast, patients in classes 3 and 4 had a high HRQoL (class 3: β=0.88; 95% CI: 0.82-0.95) or a moderate HRQoL (class 4: β=0.66; 95% CI: 0.60-0.71) at baseline and a significant decrease over time (Fig. 3) .
The baseline correlates of the estimated four classes for the EQ-5D index are reported in Table 4 . Patients in class 1 were less impaired according to clinical characteristics (UPDRS (II-IV); sum score=27.9, 95% CI: 20.7-35.1; UPDRS III=20.2, 95% CI: 15.0-25.3; 60.7% in Hoehn and Yahr stages I and II) and had a short disease duration (mean=7.0 years, 95% CI: 5.4-8.6) compared with the other classes. Classes 2 and 3 are comparable by clinical characteristics and HRQoL at baseline, whereas almost all patients in class 3 (N=7, 88%) passed away during the follow-up period resulting in a significant decrease in HRQoL over time. Latent classes 3 and 4 included patients who passed away during follow-up. The two classes differed in respect to the time of death and the mean HRQoL at baseline. Class 3 included cases of death that occurred in later follow-up waves with a high HRQoL at baseline, whereas class 4 included cases that passed away in earlier stages of follow-up. Classes 2 and 3 were comparable in baseline clinical and socio-demographic parameters. Detailed analyses are shown in Table 4 , which presents the correlates for the estimated four-class model. Patients in class 4 are characterized by a high UPDRS (II-IV) sum score (mean=84.8, 95% CI: 73.4-96.2), a long disease duration (mean=14.4, 95% CI: 11.4-17.4) and were older (mean=73.9, 95% CI: 70.2-77.5).
We also studied the EQ-VAS and the PD-specific quality of life measure PDQ-39. In both cases, the general growth mixture model also resulted in a four-class model ( Table 2 ). The pattern of EQ-VAS and PDQ-39 was comparable to the EQ-5D index within latent classes ( Table 3 ). The absolute agreement between the EQ-5D index and EQ-VAS latent classes was 78.9%, resulting in a kappa of 0.6 (P < 0.001). More than 50% (56.3%) of the subjects were classified in the same latent class of the EQ-5D index and PDQ-39, yielding a kappa of 0.4 (P < 0.001).
Discussion
Latent longitudinal models of growth are increasingly being used in the analysis of patientreported outcomes in neurological diseases, e.g., in dementia [35, 36] and multiple sclerosis [37] .
Our study is the first to apply the growth mixture modeling technique to longitudinal changes in HRQoL in patients with PD. We successfully determined four subgroups of patients that differed in their course of HRQoL across a 36-month study period. Interestingly, as outlined in an earlier communication, patients do not deteriorate in the first 6 months according to the PDQ-39 instrument and the EuroQol measures [13] . The trajectories in classes 1 and 2 did not show a considerable decline over the 3 years of the study, but had different initial intercepts. In comparison, patients in classes 3 and 4 experienced a substantial decrease in HRQoL following a lower initial status compared to classes 1 and 2. As expected, members of latent class 4, who showed the most severe trajectory, had a significantly longer duration of disease and higher UPDRS values. Nearly all patients (90%) in class 3 passed away during the 36-month study, having a moderate quality of life at baseline followed by a large decline. Patients in class 4 were older and were characterized by a lower level of HRQoL and a low level of clinical parameters at baseline. Altogether, PD patients were split into patients with a decline in HRQoL (latent classes 3 and 4) and those with a stable HRQoL (latent classes 1 and 2) over time.
We developed three separate models for the HRQoL measures assessed in this study: 1) the EQ-5D index score; 2) the EQ-VAS score; and 3) the PDQ-39. Although all three models gave four latent classes, this fact must be interpreted with caution. Due to the absolute agreement between these measures in the assignment of class membership, we reason that there is also a high level of agreement regarding what is measured in terms of HRQoL and responsiveness to PD progression. However, the psychometric characteristics differ completely between the three scales [2] . Thus, a higher level of agreement would not necessarily be expected even if the statistical power were increased by larger sample sizes and the inclusion of more covariates. Latent growth modeling should be considered as an appropriate method when comparing the responsiveness of PD scales to change over time.
The application of growth mixture modeling allows for considering the investigated outcome over time and for modeling unobserved heterogeneity among patients rather than considering a single growth rate. This method can detect changes in outcome measures not only in a group of patients, but also individual differences in changes in outcome rates among group members. The mixture model approach considers the fact that individuals within a certain population start and end at different points with regard to their HRQoL measures over the longitudinal study period [38] . The growth mixture models are used to detect subgroups of individuals by usage of a latent class membership variable [29] . In other words, growth mixture modeling investigates whether there is enough homogeneity in changes over time to allow the separation of classes of individuals who differ with regard to their baseline measures and rates of change over time.
Although we carefully designed the analyses, there are several limitations to this study. The patients were consecutively enrolled in the participating study centers without a randomization protocol. However, this convenience sample could be considered to be representative for patients suffering from Parkinson's disease in the region North Hessia, Germany. Furthermore, we present a latent general growth mixture model for HRQoL in a sample of 145 patients with Parkinson's disease. The sample size might limit our approach as follows: 1) the baseline value (intercept) of HRQoL was adjusted for BDI, UPDRS III+IV, and gender (Fig. 2) . With a larger sample size, additional covariates could have extended the modeling framework in terms of its predictive power from the intercept towards class membership.
2) It would have been possible to include time-varying covariates, since the change in HRQoL over time (slope) depends on the course of disease severity. Modeling was also conducted using time varying covariates BDI and UPDRS III+IV, but the algorithm for parameter estimation did not converge normally; and 3) the sample was characterized by a clustered design in terms of different recruitment settings. The introduction of a multilevel growth model would have provided an alternative for estimating standard errors accounting for the patients' characteristics within study centers. This approach would also require a larger sample size. Thus, we conclude that a larger sample size would be necessary to obtain stable parameter estimates for a more complex model with time-varying covariates. Nevertheless, the sample size of this study was appropriate for robust parameter estimates and convergence of the estimation algorithm when using a growth mixture model with a small number of covariates [39] .
To test the robustness of our assumption about using the worst possible score in EuroQol and PDQ-39 for the 23 patients who passed away, we applied the last observation carried forward method (LOCF) and multiple imputations by chained equations (MICE). The latent growth mixture models for the EQ-5D index, EQ VAS, and PDQ-39 in the LOCF data resulted in a three-class solution based on fit indices. The main difference was the collapsing of class 3 and 4 into a single class compared to the models reported in Table 3 (see Appendix Table 2 This fact could be caused by the LOCF approach. The within-subject variance is reduced for patients with missing values imputed by the LOCF method, resulting in a constant course of HRQoL across follow-up for these patients. In contrast, the course of HRQoL across time is estimated in the other missing value models applied in this study. There are remarkable differences in the clinical characteristics at baseline between classes 3 and 4 of the model described in Table 3 . Patients of the two classes differ significantly with respect to time of death, age, duration of disease and disease severity (Hoehn and Yahr, UPDRS). Application of the MICE approach for estimating the missing values resulted in a four-class solution comparable to the final model reported in Table 3 .
We cannot rule out the possibility that other covariates that were not included in the model may have influenced the HRQoL trajectories. In particular, non-motor symptomspsychiatric complications, sleep disturbances, and autonomic disturbances -that are known to reduce HRQoL, were not considered. Interestingly, a recent latent variable model study classified PD patients into four latent classes according to psychiatric and cognitive functioning. Age, disease severity, and medication use predicted class membership [40] . Further extensions of this pilot study should assess and include these influences as well as comorbidities, which are shown to have an independent negative effect on therapy outcome and health-related quality-of-life [41, 42] .
Previous studies that investigated changes in HRQoL over time in patients with PD using linear models assumed that individuals follow the same mean trajectory [10, 13, 43, 44] . Conventional methods overlooked individual differences in changes, regarding them as random error [45] . Longitudinal studies of PD using observation periods of 2 years and more have shown deterioration in HRQoL-scores over time [10, 43, 44] . Shorter observation periods lead to inconsistent results [13] .
In conclusion, this study provides new information on the longitudinal development of HRQoL in patients with PD over a period of 36 months. Different classes or groups were identified with substantial differences in the evolution of HRQoL over time. Interestingly, there are groups of patients whose HRQoL remains stable over longer periods of time. The classification of HRQoL subgroups may help to explain the response of PD patients to the natural history of the disease. Future research is required to identify the potential responder subgroups in terms of HRQoL on different treatment regimens. This may also allow for more targeted and systematic PD therapy.
